Short answer · Medically reviewed summary · Last updated: 2026-05-08
Myelodysplastic Syndromes (MDS) are a group of blood disorders caused by the ineffective production of healthy blood cells in the bone marrow, primarily due to acquired genetic mutations. While the exact cause for most cases remains unknown, they are generally triggered by a combination of aging, environmental exposures, and accumulated damage to the DNA of bone marrow stem cells. What causes Myelodysplastic Syndromes? In Myelodysplastic Syndromes, the bone marrow's "factory" for blood cells begins to malfunction.
Myelodysplastic Syndromes (MDS) are a group of blood disorders caused by the ineffective production of healthy blood cells in the bone marrow, primarily due to acquired genetic mutations. While the exact cause for most cases remains unknown, they are generally triggered by a combination of aging, environmental exposures, and accumulated damage to the DNA of bone marrow stem cells.
In Myelodysplastic Syndromes, the bone marrow's "factory" for blood cells begins to malfunction. Instead of producing mature, healthy red cells, white cells, and platelets, it creates immature, defective cells that often die before they can enter the bloodstream. Think of it like a photocopier that starts producing blurry, unusable documents because of a glitch in its internal programming; over time, these "glitches" (mutations) accumulate, leading to the clinical presentation of Myelodysplastic Syndromes.
Most cases of Myelodysplastic Syndromes are "de novo," meaning they are not inherited from parents. These are somatic mutations, which occur spontaneously in an individual’s cells during their lifetime. However, a small subset of patients may have a germline predisposition, where a genetic trait passed down through families increases the risk of developing these conditions. Genetic counseling is often recommended for younger patients or those with a strong family history of hematologic malignancies.
While the cause is often idiopathic (unknown), researchers have identified several key factors that increase the risk of developing Myelodysplastic Syndromes:
The exact etiology of Myelodysplastic Syndromes is still an active area of research. Modern genomic sequencing has revealed that nearly 90% of patients carry at least one somatic mutation in genes like SF3B1, TET2, or ASXL1. Current research is focused on how these mutations interact with the bone marrow microenvironment to "crowd out" healthy cells.
Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment.